Tennessee CME Requirements and CME Courses
1 - 4 of 4 results
CMEinfo Insider is developed for medical professionals who want to save time & money. Get a $3,200 Amazon® gift card or save up to $3,200 when you join today!
Stay current on cutting edge content in your primary specialty, with a limitless opportunity to research topics important to you and your patients, earn unlimited AMA PRA Category 1 Credits,™ and take advantage of exceptional CME gift card opportunities.
A World of Medical Information at Your Fingertips
We partner with premier medical teaching institutions, professional associations, and highly regarded clinicians to deliver top-notch CME activities. They bring you the most relevant medical information for you to review and apply in your own practice.Connect to CMEinfo Insider and get:
All DEA-registered practitioners have training requirements due at DEA registration renewal. With the enactment of the Consolidated Appropriations Act of 2023, the DEA now requires you to complete a one-time, eight-hour training requirement on the treatment and management of patients with opioid substance use disorders. PRESENT offers On-Demand Lectures Modules to complete your DEA CME requirements. Required for all renewals and new DEA registrations, this program was developed and accredited by AffinityCE, an ACCME Accredited and DEA-Qualified Provider.
See full details chevron_rightThe BoardVitals Addiction Medicine CME Review offers clinicians 40 AMA PRA Category 1 CreditsTM and over 700 Addiction Medicine board review questions. The questions cover key topics including recognition, intervention, and treatment of addiction. This question bank will assist clinicians with Addiction Medicine certification and recertification.
The BoardVitals Addiction Medicine CME Review also features:
After completing this activity, you should be able to:
Target Audience: Care providers concerned about issues of chronic pain and substance abuse.
See full details chevron_rightAccording to the 2015 National Survey on Drug Use and Health, approximately 3.8 million people (1.4% of those ages 12 or older) reported misusing prescription pain relievers, while another 329,000 people reported using heroin. Within the same year, 52,404 lethal overdoses took place, making drug overdose the leading cause of accidental death within the United States. Stancliff et al estimated that as of 2012, approximately 80% of people dependent on heroin or prescription opioids were not engaged in any treatment and many in treatment do not use the most effective medication-assisted treatments available to them.
Despite recent increased awareness of opioid use disorder (OUD) and efforts to improve access to care, several barriers to treatment still exist, including financial, geographic, regulatory, and social. In 2012, only 2.2% of physicians in the United States obtained waivers to prescribe buprenorphine for the treatment of OUD. Of those who received waivers, 41.6% were psychiatrists. This may be perceived as a potential barrier to OUD treatment as patients are often resistant to referrals to psychiatric and/or addiction clinics given the stigmas commonly surrounding addiction and mental health. Furthermore, physicians with waivers were found to practice primarily in urban settings, leaving a large portion of the rural population without access to buprenorphine treatment.
With all this in mind, education is needed in regards to current and emerging treatment options for OUD available to multiple patient populations. Also, with the deaths due to drug overdoses still elevated, education on how to recognize and reverse an opioid overdose is needed.
This presentation will address the above needs by discussing the science behind opioid use disorder as well as reflect upon current statistics associated with its impact on the United States. During the discussion, opioid overdose risks will be discussed and participants will be able to practice recognizing key symptoms of an overdose situation. Steps of using naloxone will be discussed and connected to how to appropriately seek out treatment for maintenance of opioid use disorder. Finally, new buprenorphine products and the potential role of naltrexone will be applied to this stigmatized population.
See full details chevron_rightReceive special offers, keep up with MOC requirements and stay informed of the latest offerings in free online CME in your specialty.